From Wikipedia, the free encyclopediaJump to navigation Jump to search
|Chemical and physical data|
|Molar mass||163.219 g·mol−1|
|3D model (JSmol)|
|NY (what is this?)|
ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.
- Jain KK (January 2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
- Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
- Xu N, Kim GE, Gregg H, Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA (September 2004). "Automated 96-well liquid-liquid back extraction liquid chromatography-tandem mass spectrometry method for the determination of ABT-202 in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 36 (1): 189–95. doi:10.1016/j.jpba.2004.05.013. PMID 15351065.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|
Retrieved from "https://en.wikipedia.org/w/index.php?title=ABT-202&oldid=978759361"